Meningioma Tumors: Detection of Subgroups

  • Daniel Monleon
  • Concha López-Ginés
  • Rosario Gil-Benso
  • Jose Manuel González-Darder
  • Miguel Cerdá-Nicolas
Part of the Tumors of the Central Nervous System book series (TCNS, volume 7)


Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord and represent around 20% of all central nervous system tumors. Medical writings from as early as the eighteenth century make reference to tumors arising from the meninges. The current standards for diagnosis of meningiomas are clinical and pathological findings. The World Health Organization (WHO) classifies meningiomas into three histological grades: grade I (benign), grade II (atypical), and grade III (anaplasic) in accordance with the clinical prognosis. In absolute numbers, most recurrent meningiomas correspond to histological benign tumours. The potential aggressiveness of an individual meningioma is still difficult to evaluate. Due to the potential recurrence of some meningioma regardless of the histological grade, the management of the meningioma patients must include an appropriate follow up strategy suited to the grade of surgical resection and the likelihood of recurrence in individual cases. The detection of new meningioma subgroups with clinical and biological relevance may help in these strategies. This review summarizes the most recent advances in the detection of meningioma subgroups using traditional and modern high throughput molecular techniques. Most relevant results on studies of meningioma using cytogenetics, proteomics, transcriptomics and metabolomics suggest that there are at least two molecular subgroups of histological benign meningiomas. These two subgroups exhibit very distinct genetic and biochemical properties and show different levels of metabolic aggressiveness. The assignment of individual meningiomas to one of these subgroups simultaneously to the traditional histopathological examination may improve the management of these tumors.


Atypical Meningioma Benign Meningioma Anaplastic Meningioma Meningioma Patient Clear Cell Meningioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to acknowledge the funding sources that helped in the development of their research, part of which is reviewed here, in the recent years. The following funding sources are gratefully acknowledged: Consellería de Sanidad (GV-AP064/07, GV-AP076/08, GV-AP014/09, GV-AP119/10 and GV-AP023/10) and the Consellería de Educación (PROMETEO11/2011/083, FPA/2011/054, ACOMP2009-200, ACOMP2010-184 and ACOMP2011-237) de la Generalitat Valenciana, the Ministerio de Educación y Ciencia del Gobierno de España (SAF2008-00270, and Ramon y Cajal Contract 2006).


  1. Aarhus M, Lund-Johansen M, Knappskog PM (2011) Gene expression profiling of meningiomas: current status after a decade of microarray-based transcriptomic studies. Acta Neurochir (Wien) 153:447–456CrossRefGoogle Scholar
  2. Balendiran GK, Dabur R, Fraser D (2004) The role of glutathione in cancer. Cell Biochem Funct 22:343–352PubMedCrossRefGoogle Scholar
  3. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229PubMedCrossRefGoogle Scholar
  4. Cerda-Nicolas M, Lopez-Gines C, Perez-Bacete M, Barcia-Salorio JL, Llombart-Bosch A (2000) Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumors. J Neurooncol 47:99–108PubMedCrossRefGoogle Scholar
  5. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG (1997) Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94:6408–6413PubMedCrossRefGoogle Scholar
  6. Cullis PR, Hope MJ, Tilcock CP (1986) Lipid polymorphism and the roles of lipids in membranes. Chem Phys Lipids 40:127–144PubMedCrossRefGoogle Scholar
  7. Cushing H, Eisenhardt L (1938) Meningiomas. Hafner Publishing Co Ltd, New YorkGoogle Scholar
  8. Dumanski JP, Rouleau GA, Nordenskjold M, Collins VP (1990) Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 50:5863–5867PubMedGoogle Scholar
  9. Filomeni G, Aquilano K, Rotilio G, Ciriolo MR (2005) Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis. Cancer Res 65:11735–11742PubMedCrossRefGoogle Scholar
  10. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, Lee YS, Bhowmick DA, Lubensky IA, Oldfield EH, Zhuang Z (2004) Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23:6806–6814PubMedCrossRefGoogle Scholar
  11. Glunde K, Jacobs MA, Bhujwalla ZM (2006) Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 6:821–829PubMedCrossRefGoogle Scholar
  12. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, Yamaura A (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64:2496–2501PubMedCrossRefGoogle Scholar
  13. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E (2001) NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367–372PubMedCrossRefGoogle Scholar
  14. Lopez-Gines C, Cerda-Nicolas M, Barcia-Salorio JL, Llombart-Bosch A (1995) Cytogenetical findings of recurrent meningiomas. A study of 10 tumors. Cancer Genet Cytogenet 85:113–117PubMedCrossRefGoogle Scholar
  15. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, Roldan P, Llombart-Bosch A (2004) Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 148:123–128PubMedCrossRefGoogle Scholar
  16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRefGoogle Scholar
  17. Maillo A, Orfao A, Espinosa AB, Sayagues JM, Merino M, Sousa P, Lara M, Tabernero MD (2007) Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol 9:438–446PubMedCrossRefGoogle Scholar
  18. McLendon RE, Rosenblum MK, Bigner DD (eds) (2006) Russell & Rubinstein’s pathology of tumours of the central nervous system. Hodder Arnold, LondonGoogle Scholar
  19. Monleon D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortes O, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Celda B (2008) Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res 7:2882–2888PubMedCrossRefGoogle Scholar
  20. Monleon D, Morales JM, Gonzalez-Segura A, Gonzalez-Darder JM, Gil-Benso R, Cerda-Nicolas M, Lopez-Gines C (2010) Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res 70:8426–8434PubMedCrossRefGoogle Scholar
  21. Nicholson JK, Lindon JC (2008) Systems biology: metabonomics. Nature 455:1054–1056PubMedCrossRefGoogle Scholar
  22. Nicholson JK, Connelly J, Lindon JC, Holmes E (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1:153–161PubMedCrossRefGoogle Scholar
  23. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Glasker S, Sohn TS, Zeng W, Ikejiri B, Proescholdt MA, Mayer C, Weil RJ, Oldfield EH, Zhuang Z (2006) Comparative proteomic profiles of meningioma subtypes. Cancer Res 66:10199–10204PubMedCrossRefGoogle Scholar
  24. Opstad KS, Provencher SW, Bell BA, Griffiths JR, Howe FA (2003) Detection of elevated glutathione in meningiomas by quantitative in vivo 1H MRS. Magn Reson Med 49:632–637PubMedCrossRefGoogle Scholar
  25. Orlowski M (1976) Possible role of glutathione in transport processes. Adv Exp Med Biol 69:13–28PubMedGoogle Scholar
  26. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455–1465PubMedCrossRefGoogle Scholar
  27. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046–2056PubMedGoogle Scholar
  28. Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neurooncol 70:183–202PubMedCrossRefGoogle Scholar
  29. Pfisterer WK, Hank NC, Preul MC, Hendricks WP, Pueschel J, Coons SW, Scheck AC (2004) Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol 6:290–299PubMedCrossRefGoogle Scholar
  30. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC (2008) Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol 87:43–50PubMedCrossRefGoogle Scholar
  31. Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH (2003) Identification of a third protein 4.1 tumor suppressor, protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 13:191–202PubMedCrossRefGoogle Scholar
  32. Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, Perry A, Gutmann DH (2011) Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 70(1):1–12PubMedCrossRefGoogle Scholar
  33. Warburg O (1956) On the origin of cancer cells. Science 123:309–314PubMedCrossRefGoogle Scholar
  34. Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307–314PubMedCrossRefGoogle Scholar
  35. Zhang FR, Delattre O, Rouleau G, Couturier J, Lefrancois TG, Aurias A (1990) The neuroepithelioma breakpoint on chromosome 22 is proximal to the meningioma locus. Genomics 6:174–177PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Daniel Monleon
    • 1
  • Concha López-Ginés
    • 1
  • Rosario Gil-Benso
    • 1
  • Jose Manuel González-Darder
    • 1
  • Miguel Cerdá-Nicolas
    • 1
  1. 1.Fundacion de Investigacion del Hospital Clinico Universitario de ValenciaValenciaSpain

Personalised recommendations